Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  966 results for ""RITUXIMAB""

Your Filters

Geographic : india
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort.

  • Authors : Sawhney S; Division of Pediatric Rheumatology, 28928Sir Ganga Ram Hospital, Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India.; Agarwal M

Subjects: Immunologic Factors*/Immunologic Factors*/Immunologic Factors*/adverse effects ; Immunologic Factors*/Immunologic Factors*/Immunologic Factors*/therapeutic use ; Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/complications

  • Source: Lupus [Lupus] 2021 Oct; Vol. 30 (11), pp. 1829-1836. Date of Electronic Publication: 2021 Jul 27.Publisher: SAGE Publications Country of Publication: England NLM ID: 9204265 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India.

  • Authors : Nair R; Department of Clinical Haematology and HCT, Tata Medical Center, Kolkata, India. Electronic address: .; Radhakrishnan VS

Subjects: Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/Antineoplastic Agents, Immunological/*therapeutic use ; Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*therapeutic use ; Lymphoma, B-Cell/Lymphoma, B-Cell/Lymphoma, B-Cell/*drug therapy

  • Source: The Lancet. Haematology [Lancet Haematol] 2021 Aug; Vol. 8 (8), pp. e548-e549.Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026

Record details

Read More Add to Saved list
×
Academic Journal

Rituximab in maintaining remission in adults with podocytopathy.

  • Authors : Ramachandran R; Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.; Bharati J

Subjects: Glomerulosclerosis, Focal Segmental*/Glomerulosclerosis, Focal Segmental*/Glomerulosclerosis, Focal Segmental*/diagnosis ; Glomerulosclerosis, Focal Segmental*/Glomerulosclerosis, Focal Segmental*/Glomerulosclerosis, Focal Segmental*/drug therapy ; Glomerulosclerosis, Focal Segmental*/Glomerulosclerosis, Focal Segmental*/Glomerulosclerosis, Focal Segmental*/physiopathology

  • Source: Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2020 Aug; Vol. 25 (8), pp. 616-624. Date of Electronic Publication: 2020 Jun 14.Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.

Subjects: Nephrotic Syndrome*/Nephrotic Syndrome*/Nephrotic Syndrome*/drug therapy ; Nephrotic Syndrome*/Nephrotic Syndrome*/Nephrotic Syndrome*/etiology ; Nephrotic Syndrome*/Nephrotic Syndrome*/Nephrotic Syndrome*/immunology

  • Source: Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2019 Dec; Vol. 24 (12), pp. 1241-1247. Date of Electronic Publication: 2019 May 01.Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Use of rituximab in muscle-specific tyrosine kinase antibody-positive myasthenia gravis: Preliminary observations from a tertiary care center in Northern India.

  • Authors : Sachdeva J; Department of Neurology, Postgraduate Institute of Medical and Research, Chandigarh, India.; Mahesh KV

Subjects: Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Myasthenia Gravis/Myasthenia Gravis/Myasthenia Gravis/*drug therapy ; Rituximab/Rituximab/Rituximab/*therapeutic use

  • Source: Indian journal of pharmacology [Indian J Pharmacol] 2020 Jan-Feb; Vol. 52 (1), pp. 49-52. Date of Electronic Publication: 2020 Mar 11.Publisher: Medknow Publications Country of Publication: India NLM ID: 7902477 Publication Model: Print-Electronic Cited

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.

  • Authors : De D; Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.; Bishnoi A

Subjects: Immunologic Factors/Immunologic Factors/Immunologic Factors/*therapeutic use ; Pemphigus/Pemphigus/Pemphigus/*drug therapy ; Rituximab/Rituximab/Rituximab/*therapeutic use

  • Source: Indian journal of dermatology, venereology and leprology [Indian J Dermatol Venereol Leprol] 2020 Jan-Feb; Vol. 86 (1), pp. 39-44.Publisher: Scientific Scholar on behalf of Indian Association of Dermatologists, Venereologists & Leprologists Country of Publication: United States NLM ID: 7701852

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Long‐term efficacy and safety analysis of single cycle of biosimilar rituximab in pemphigus: A retrospective study of 76 patients from India.

Subjects: *RITUXIMAB; *PEMPHIGUS; *PREDNISOLONEINDIA

  • Source: Dermatologic Therapy. Sep2022, Vol. 35 Issue 9, p1-6. 6p.

Record details

Read Online Read More Add to Saved list
×
Academic Journal

Risk of tuberculosis among renal transplant recipients receiving rituximab therapy.

Subjects: *KIDNEY transplantation; *RITUXIMAB; *TUBERCULOSISINDIA

  • Source: Transplant Infectious Disease. Dec2022, Vol. 24 Issue 6, p1-7. 7p.

Record details

Read Online Read More Add to Saved list
×
Academic Journal

The Profile of Use of Rituximab in Tertiary Care Hospitals of Central India.

Subjects: RITUXIMAB; TERTIARY care; NON-Hodgkin's lymphomaINDIAUNITED States. Food & Drug Administration

  • Source: Journal of Pharmacy & Bioallied Sciences; Oct-Dec2022, Vol. 14 Issue 4, p191-195, 5p

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of rituximab in central nervous system demyelinating disorders.

Subjects: RITUXIMAB; DRUG efficacy; MULTIPLE sclerosisINDIA

  • Source: Annals of Indian Academy of Neurology; Sep/Oct2021, Vol. 24 Issue 5, p732-739, 8p

Record details

Read More Add to Saved list
×
  • 1-10 of  966 results for ""RITUXIMAB""